NeuroRx Inc.

When lives are at stake there is no time to waste.

Our talented team of scientists, determined to do their part to contribute to the fight against the worst healthcare disaster in 100 years, had a brilliant idea to repurpose a legacy compound, RLF-100TM (aviptadil), a recombinant form of a naturally occurring peptide found in the lung - Vasoactive Intestinal Peptide (VIP) -  to protect the lung from injury due to COVID-19. Taking advantage of the extraordinary measures implemented in the U.S. to speed up clinical research for COVID-19 therapeutics, Relief partnered with NeuroRx Inc., a U.S. based biotech that excels at innovative novel therapeutic development for rapid deployment. Ten weeks from concept to clinic, we began our journey to providing this potentially life-saving drug to critical COVID-19 patients.

Learn more about RLF-100™

On September 21, 2020, Relief and NeuroRx announced the completion of their partnership agreement for the commercialization of RLF-100™ worldwide. They have agreed that NeuroRx will lead commercialization in the United States, Canada, and Israel, while Relief will lead commercialization in Europe and the rest of the world.

Preparing for U.S. Commercialization

Relief and NeuroRx have also taken steps to increase manufacturing of RLF-100™ to prepare for commercialization in case of FDA approval. The companies have contracted with Nephron Pharmaceuticals, Inc. to manufacture, fill & finish, commercial supplies of RLF-100™ in order to ensure that adequate drug inventory will be immediately available. Similarly, they have contracted with Bachem Americas to manufacture sufficient RLF-100™ drug substance to supply 1 million doses. Bachem was the first peptide manufacturer to synthesize RLF-100™ and has played a leading role in the development of the drug substance over the past 20 years. An additional contract was established with a leading nationwide pharmaceutical logistics partner to ensure overnight supply to U.S. hospitals.